ARCHIVES

Drug Approvals; Zykadia Granted Accelerated Approval For ALK+ NSCLC; ADXS-HPV Grated Orphan Drug Designation

This article is from The Cancer Letter archive.

Vol. 40 No. 19 | May 9, 2014

Download PDF Visit The Full Archive

Related Articles

Targeting Men At High Risk Finds More Head & Neck Cancer

September 24, 2010

New Structure Of Divisions Outlined

September 15, 1995

NCAB Member Becker Says AACR ‘Feels Disenfranchised’

December 6, 1991

Shubik Warns NCA Members They May Be Prober’s Next Target

May 22, 1981

Duke Picks Lyerly To Direct Cancer Center

May 2, 2003

FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion

January 3, 1992